Document is current

Article History

Received: 23 June 2020

Revised: 7 September 2020

Accepted: 2 October 2020

First Online: 22 October 2020

Ethics approval and consent to participate

: Ethics board approval was obtained for this project from Alfred Health. The requirement for consent from subjects to participate in the project was waived by the ethics board. The study was performed in accordance with the Declaration of Helsinki.

: Data supporting the results reported in this article is stored at Alfred Health and can be provided upon request.

: P.B.: Travel support: MSD G.V.L.: Consultancy: Aduro, Amgen, Bristol-Myers Squibb, Mass-Array, Merck, MSD, Novartis, OncoSec Medical, Pierre Fabre, Roche, QBiotics, Skyline DX and Sandoz. A.M.M.: Consultancy: BMS, MSD, Novartis, Roche, Pierre-Fabre. Acknowledgement Cancer Institute NSW Fellowship and Melanoma Institute Australia. VA. Consultancy: BMS, MSD, Merck, Novartis, Pierre Fabre, Roche, NEKTAR. Speaker honoraria: BMS, MSD, Merck, Novartis. Travel support: BMS, Oncosec. J.V.C.: Consultancy: Sanofi-Genzyme, BMS. R.J.S.: Consultancy: Asana Biosciences, Bristol Myers Squibb, Novartis, Merck, Lovance. Research funding: Merck, Amgen. M.N.: Consultancy: Novartis, BMS, Pierre-Fabre. Speaker honoraria: Novartis, BMS, Pierre-Fabre. K.K.: Personal fees: Amgen, Roche, Bristol Myers Squibb, Merck Sharp and Dohme, Novartis, Amgen, Pierre Fabre, Medac. A.H.: Consultancy: Amgen, BMS, MerckSerono, MSD/Merck, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, OncoSec, Sanofi-Genzyme, Sun Pharma, Novartis Pharma, Almirall Hermal. Speaker honoraria: Amgen, BMS, MSD/Merck, Pierre Fabre, Provectus, Regeneron, Roche, Sanofi-Genzyme Novartis Pharma. Research funding: Amgen, BMS, MerckSerono, MSD/Merck, Philogen, Pierre Fabre, Provectus, Regeneron Roche, Sanofi-Genzyme, Novartis Pharma. R.P.: Consultancy: Pierre Faber, Bayer, Octimet, Clovis Oncology, Novartis, Karus Therapeutics, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics, Sanofi Aventis. Speaker honoraria: AstraZeneca, Novartis, Bayer, Tesaro, BMS. Travel support: BMS, MSD. P.A.A.: Consultancy: Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. Research funding: Bristol Myers-Squibb, Roche-Genentech, Array. Travel support: MSD. L.Z.: Consultancy: BMS, Novartis, Pierre Fabre, Sunpharma, Sanofi, MSD. Honoraria from Roche, BMS, MSD, Novartis, Pierre Fabre. Research funding: Novartis; Travel support: BMS, Pierre Fabre, Sanofi, Amgen, Novartis, Sunpharma. D.S.: Consultancy: BMS, Merck Serono, Amgen, Immunocore, Incyte, 4SC, Pierre Fabre, Mologen, Merck/MSD, Sanofi/Regeneron. Speaker honoraria: Roche/Genentech, Novartis, BMS, Merck Serono, Amgen, Immunocore, Incyte, 4SC, Pierre Fabre, Array BioPharma, InFlarX, Philogen, Regeneron, Merck/MSD, Sandoz/Hexal, Neracare. Research funding: Novartis, BMS. Travel support: Roche/Genentech, Novartis, BMS, Merck Serono, Amgen, Merck/MSD. C.A.: Travel support: Amgen, BMS, Roche. C.L.: Consultancy: Avantis Medical Systems, BMS, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi. Research funding: BMS, Roche. Speaker honoraria: BMS, MSD, Novartis, Amgen, Roche, Pierre Fabre, Pfizer, Incyte. Travel support: BMS, MSD, CR: Consultancy: BMS, Pierre Fabre, Novartis, Merck, MSD, Roche, Sanofi, Biothera, Curevac. T.L.: Consultancy: MSD, Pierre Fabre, Novartis. S.P.: Speaker honoraria: Merck CUB: Consultancy: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures. Research funding: BMS, Novartis, NanoString. Stockowner: Uniti Cars. A.K.: Speaker honoraria: Novartis. Travel support: Novartis. A.V.W.: Travel support: BMS, Novartis, MSD. M.S.C.: Consultancy: BMS, MSD, Novartis, Amgen, Roche, Pierre Fabre, Nektar, Eisia, Sanofi, Merck Serono, Ideay, Q biotics. M.S.: Consultancy: BMS, Merch, MSD. Speaker honoraria: BMS, Merck, MSD. Research funding: BMS. Travel support: BMS, Merck, Roche. A.H.: Consultancy: Novartis, BMS, MSD, Pierre-Fabre. All remaining authors have declared no conflict of interest.

: G.V.L.: acknowledgements: NHMRC Practitioner Fellowship, the University of Sydney Medical Foundation and Melanoma Institute Australia. A.M.M.: Acknowledgements: Cancer Institute NSW Fellowship and Melanoma Institute Australia.